Inclusion Criteria:

          -  Have a histologically or cytologically confirmed diagnosis of advanced solid tumor

          -  Have advanced or metastatic disease refractory to standard curative or palliative
             therapy or contraindication to standard therapy

          -  Be reasonably recovered from preceding major surgery or no major surgery within 4
             weeks prior to the start of Day 1 treatment

          -  Have a negative pregnancy test for females with child bearing age at screening and
             should not be breast feeding

          -  Be willing to abstain from sexual activity or practice physical barrier contraception
             from study entry to 6 months after the last day of treatment

        Exclusion Criteria:

          -  Have peripheral neuropathy of Grade 3 or Grade 4 at screening

          -  Have peripheral sensory neuropathy of Grade 2 or greater at screening

          -  Have an interval from previous neurotoxic drugs less than 3 months unless reasonably
             recovered from all grades of neurotoxicity to grade 1 or lower as judged by the
             investigator

          -  Have known hypersensitivity to chemotherapeutic agents

          -  Have a history of thrombocytopenia with complications including hemorrhage or bleeding
             > Grade 2 that required medical intervention or any hemolytic condition or coagulation
             disorders that would make participation unsafe

          -  Have unresolved toxicity from previous treatment or previous investigational agents;
             excluding alopecia

          -  Is pregnant or breast-feeding